BACKGROUND: Urine amino-terminal probrain natriuretic peptide (NT-proBNP) concentrations may exclude the presence of heart failure and provide insight into renal clearance mechanisms for human NTproBNP. We characterized the molecular forms of urine NT-proBNP detected by immunoassay.
Increased intracardiac pressure and volume load promote cardiac release of brain natriuretic peptide (BNP), 4 facilitating cardiac homeostasis via feedback effects on vascular tone and natriuresis (1 ) . Plasma BNP concentrations are now recognized diagnostic (2 ) and prognostic (3 ) tools in cardiovascular disorders. The cosecreted amino-terminal portion of pro-BNP (NT-proBNP) is also a discriminating plasma biomarker for detection of cardiac dysfunction (4 ) and a powerful prognostic measure of clinical outcomes in cardiovascular disorders (5, 6 ) . Plasma NT-proBNP has been incorporated into major guidelines as a tool for characterization and management of heart failure (7, 8 ) . The development of commercial assays for plasma BNP and NT-proBNP has ensured increasing use of both peptides in clinical and research settings.
Numerous recent clinical studies have applied existing plasma NT-proBNP assays to urine samples. Urine NT-proBNP immunoreactivity has been determined in physiological studies (9, 10 ) , in heart failure (11) (12) (13) (14) , for screening of left ventricular dysfunction in the community (15 ) , and for prediction of cardiovascular events in heart failure (16 ) . These studies and an editorial (17 ) suggest that urine NT-proBNP represents an alternative to plasma NT-proBNP as a clinical biomarker. Whereas previous studies support a clinical utility for urine NT-proBNP immunoreactivity, no study has provided evidence that NT-proBNP assays applied to urine actually measure authentic NTproBNP. Validation of a urine NT-proBNP assay is required before clinicians can accept urine values as an alternative to plasma NT-proBNP concentrations in heart failure care.
Characterization of urinary NT-proBNP potentially offers insight into the mechanisms for renal clearance of NT-proBNP, which are currently unknown. Knowledge of the actual molecular forms of NTproBNP material in human urine would indicate whether NT-proBNP is degraded by renal tissue after glomerular filtration and potentially explain the lim-ited NT-proBNP immunoreactivity in human urine compared with high plasma concentrations. Accordingly, we characterized the immunoreactive forms of NT-proBNP in human urine using HPLC coupled to 4 assays specific toward different epitopes of the NTproBNP molecule.
Materials and Methods

PEPTIDES
We purchased human synthetic NT-proBNP(1-76) as 20 g net peptide per vial from Phoenix Pharmaceuticals. Mass spectrometry conducted by our laboratory confirmed that the supplied peptide had a molecular weight identical to NT-proBNP(1-76). Synthetic human NT-proBNP(1-21), human NT-proBNP(1-13), and human NT-proBNP(1-13)-Tyr 14 were synthesized by Mimotopes.
SAMPLE COLLECTION
All protocols were approved by the local regional ethics committee (Ministry of Health, New Zealand), and all patients gave informed consent. We collected specimens into chilled tubes containing 7.5 mg EDTA per 5 mL blood or 3.75 mg EDTA per 1 mL urine. Within 20 min of collection, specimens were centrifuged at 3000g and 4°C for 10 min; the supernatant was stored at Ϫ80°C. Plasma (1-10 mL) and urine (60 mL) were extracted using Sep Pak C 18 cartridges (Waters) (18 ) , which were prewashed with 5 mL methanol and 5 mL 0.1% trifluoroacetic acid (TFA). The cartridge was further washed with 5 mL 0.1% TFA, and peptides were eluted with 2 mL 80% isopropanol in 0.1% TFA. After addition of 10 L 1% Triton X-100, the eluates were dried under an air stream at 37°C. We resuspended extract residues in either buffer before RIA or 20% CH 3 CN in 0.1% TFA before HPLC.
NT-proBNP ASSAYS
We measured NT-proBNP immunoreactivity using 4 NT-proBNP assays with different epitope specificities. All assays were conducted by technicians blinded to patient status. We used 2 established local assays for NT-proBNP. The first, referred to as NT-proBNP (1-13), used antiserum raised against human NTproBNP(1-13), radiolabeled NT-proBNP(1-13)-Tyr 14 , and synthetic NT-proBNP(1-21) standard, as described (19 ) . Cross-reactivities using NT-proBNP (1-13) antiserum, relative to NT-proBNP(1-21) (100%), were NT-proBNP(1-76) 58%, NT-proBNP (1-13) 77%, NT-proBNP(2-13) 15%, NT-proBNP(3-13) 3%, NT-proBNP(4 -13) 0.03%, BNP(1-32) Ͻ0.007%, atrial natriuretic peptide (ANP) Ͻ0.0005%, proANP(1-20) Ͻ0.004%, and C-type natriuretic peptide (CNP)-22 Ͻ 0.004%. Intra-and interassay CVs for this NT-proBNP assay were 6.1% and 9.9% at 800 ng/L, 6.4% and 8.6% at 1500 ng/L, and 3.5% and 7.9% at 5000 ng/L. The assay limit of detection was 8.5 ng/L.
The second local NT-proBNP assay, referred to as NT-proBNP(62-76), used antiserum raised against the carboxy-terminal residues 62-76 of NT-proBNP, [ 125 I]NT-proBNP(62-76), and synthetic NT-proBNP (1-76) standard (20 ) . Cross-reactivities using NTproBNP(62-76) antiserum, relative to NT-proBNP(1-76) (100%), were NT-proBNP(58 -76) 80%, proBNP (58 -79) 0.07%, BNP(1-32) 0.14%, ANP 0.13%, and CNP-22 0.09%. The assay limit of detection was 135 ng/L. Intraassay CVs were 7.2% between 340 and 850 ng/L, 6.2% between 850 and 1700 ng/L, and 4.7% between 1700 and 6000 ng/L.
We also used our validated BNP(1-32) assay with antiserum from Bachem (T-4021; Bachem) (21 ) . Previous work has demonstrated that our NT-proBNP(1-13) assay detects proBNP(1-108) and NT-proBNP(1-76), our NT-proBNP(62-76) assay detects NT-proBNP (1-76) but does not cross-react with endogenous proBNP(1-108), and our BNP(1-32) assay detects both proBNP(1-108) and BNP(1-32) (20 ) .
We also measured NT-proBNP immunoreactivity using first-and second-generation electrochemiluminescence immunoassays (Roche Diagnostics) on an Elecsys® 2010 analyzer. The first-generation assay (referred to as proBNP I) is based on 2 polyclonal antibodies recognizing epitopes within amino acids 1-21 and 39 -50 of NT-proBNP(1-76) and proBNP (22, 23 ) . The second-generation assay (referred to as proBNP II) is based on 2 monoclonal antibodies recognizing epitopes within amino acids 27-31 and 42-46 of NT-proBNP (Roche Diagnostics datasheet). The assay limit of detection was 5 ng/L for both assays. The interassay CV for both Roche NT-proBNP assays was Յ3.0% for concentrations up to 5500 ng/L.
SUBJECTS
Subjects were categorized into 3 groups: (1) 10 healthy individuals without a history of cardiovascular disease, (2) 20 unselected individuals with chronic heart failure (who had required hospitalization for acute heart failure within the previous 12 months), and (3) 20 unselected individuals within 8 h of hospitalization with acute heart failure. Acute heart failure was defined by Framingham criteria (24 ) and satisfied European Society of Cardiology guidelines (25 ) for heart failure. We measured plasma and urine NT-proBNP immunoreactivity in untimed samples without prior extraction using the second-generation Roche proBNP II assay. Urine NT-proBNP concentrations were adjusted for urine volume by indexing to urine creatinine measured by the standard colorimetric Jaffé reaction. We estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation (26 ) . Fractional excretion of filtered NT-proBNP was calculated after normalization of urinary and plasma NT-proBNP concentrations to the respective creatinine concentrations as in the following equation:
Fractional excretion NT-proBNP (%) ϭ urinary NT-proBNP Ϭ urine creatinine plasma NT-proBNP Ϭ plasma creatinine ϫ 100
In all heart failure subjects, a transthoracic echocardiogram was obtained using a Vivid 3 machine (General Electric) within 48 h of urine sampling. The standardized imaging protocol included apical 4-and 2-chamber views according to the American Society of Echocardiography (27 ) . Parasternal short-and longaxis views (averaged over 4 cycles) were obtained for M-mode measurements of left ventricular dimensions. Left ventricular volumes were calculated from apical 4-and 2-chamber views using the method of discs formula. Biplane systolic and diastolic volumes and ejection fraction were calculated by planimetry according to Simpson's method.
STABILITY OF NT-proBNP IMMUNOREACTIVITY IN URINE
To assess the effect of urinary degradation on NTproBNP immunoreactivity, we collected urine from 3 patients with acute heart failure. The samples were supplemented, with and without prior addition of EDTA, to 2500 ng/L with synthetic human NT-proBNP(1-76). Samples were incubated for 0, 30, 60, and 120 min at 37°C. Incubated aliquots were removed at each time point, snap-frozen on dry ice, and stored at Ϫ80°C before immunoassay.
HPLC ANALYSIS
We performed size-exclusion HPLC analysis on urine extracts from 3 patients and a pooled plasma extract from 2 patients, all with acute heart failure. We separated extracts using a TSK-GEL G2000SW (7.5 by 600 mm; Toyo Soda) column equilibrated with 20% CH 3 CN (ChromAR; Malinckrodt Baker Inc.) in 0.1% TFA (Uvasol; Merck KGaA) at 0.5 mL/min. After addition of 10 L 1% Triton X-100, 0.5-mL fractions were dried under an air stream at 37°C and reconstituted in assay buffer. The column was calibrated with the molecular weight (MW) standards cytochrome C (12.4 kDa), NT-proBNP (8.5 kDa), aprotinin (6.5 kDa), BNP (3.5 kDa), ANP (3.1 kDa), angiotensin II (1.0 kDa), and tyrosine (0.18 kDa).
We also separated urine (60 mL) and plasma (3.8 mL) extracts from patients with acute heart failure by reversed-phase HPLC. We used a Phenomenex Jupiter C18 300A (250 by 4.60 mm, 5 m) column running a linear gradient of 0%-60% CH 3 CN in 0.1% TFA at 1 mL/min over 60 min. Sample extract and synthetic NTproBNP(1-76) standard were run consecutively with both plasma and urine extracts. After adding 1% Triton X-100 (10 L), 0.5-mL HPLC fractions were dried under an air stream at 37°C and reconstituted in buffer. Because the reversed-phase HPLC runs were conducted some months apart with differing batches of solvent, there were minor differences in the elution position of synthetic NT-proBNP(1-76) standard.
STATISTICAL ANALYSIS
Clinical results were calculated as mean (SD) or median and interquartile range (IQR) for nonparametric data. Nonparametric data were log-transformed before analysis to stabilize variances. Where urine NTproBNP immunoreactivity was undetectable, the urine concentration was assumed to be equal to the assay limit of detection (5 ng/L) for indexation to urine creatinine. We tested agreement between actual and expected endogenous NT-proBNP immunoreactivity after serial dilution of extracted samples as determined by the Roche proBNP II assay using the method of Bland and Altman (28 ) . The ratio between actual and expected NT-proBNP values was plotted against their mean.
Correlation coefficients were calculated using Pearson product-moment correlation. Independent t tests and 2 tests were used to compare continuous or categorical variables, respectively, between groups of subjects. P values Ͻ0.05 were taken to indicate statistical significance. All data analyses were prepared using SPSS version 13 (SPSS Inc.).
Results
Serial 2-fold dilutions of urine extracts from patients with heart failure were parallel to standard curves of the NT-proBNP(1-13) and NT-proBNP(62-76) immunoassays (Fig. 1) . Using the Bland-Altman method, we observed agreement between actual and expected concentrations of endogenous NT-proBNP immunoreactivity detected by the second-generation Roche assay for serial dilutions of urine extracts. The mean ratio between actual and expected NT-proBNP values was 1.17 (0.27) across a wide range of NT-proBNP immunoreactivity (8.5-200 000 ng/L).
IN VITRO DEGRADATION OF NT-proBNP IN URINE
NT-proBNP(1-13) immunoreactivity was stable in urine during 2 h of incubation at 37°C. By contrast, NT-proBNP(62-76) immunoreactivity in urine decreased by approximately 50% in 2 h. Loss of NT-proBNP(62-76) immunoreactivity was prevented by prior addition of EDTA (Fig. 2) .
CHARACTERIZATION OF NT-proBNP MOLECULAR FORMS IN URINE USING HPLC
Separation of urine extracts by HPLC was conducted on samples from patients with acute decompensated heart failure; HPLC fractions of urine extracts from subjects with chronic heart failure were below the limits of detection for the NT-proBNP immunoassays used. Size-exclusion chromatography of heart failure plasma identified a single, well-defined peak of endogenous NT-proBNP immunoreactivity eluting at the position of synthetic human NT-proBNP(1-76) for both NT-proBNP(1-13) and NT-proBNP(62-76) assays (Fig. 3) . In contrast, the HPLC profile of endogenous NT-proBNP immunoreactivity in heart failure urine was markedly heterogeneous (Fig. 3) . In all 3 urine samples, the peak of highest MW NT-proBNP eluted at a lower MW than synthetic NT-proBNP(1-76) [fractions 28 -29 (6.1 kDa)]. This material was immunoreactive in the NT-proBNP(1-13) assay but was not detected by the NT-proBNP(62-76) assay. Because the NT-proBNP(1-13) assay requires the first 3 residues of NT-proBNP for maximal immunoreactivity, this result suggests that a proportion of the highest MW peak observed in the urine chromatogram was NTproBNP truncated by proteolytic degradation at the carboxy terminus. The loss of MW equivalent to about 2.5 kDa in this major chromatographic peak compared with the known NT-proBNP(1-76) MW of 8.5 kDa is suggestive of NT-proBNP cleavage near residues 55-58.
An HPLC peak was always detected at fractions 30 -32 (Fig. 3) by the NT-proBNP(1-13) and both Roche NT-proBNP assays, consistent with a smaller NT-proBNP fragment of MW 2-3.5 kDa. A number of intermediate elution peaks of variable MWs were observed, representing numerous variably degraded NTproBNP peptides. Minimal BNP immunoreactivity was identified in size-exclusion HPLC fractions excluding proBNP as an important contributor to the NT-proBNP immunoreactivity profile we observed (data not shown).
Separation of heart failure plasma by reversedphase HPLC demonstrated elution of NT-proBNP NT-proBNP immunoreactivity was determined using synthetic NT-proBNP(1-21) and antiserum directed to the amino terminal portion (amino acids 1-13) of NT-proBNP (upper panel) and using synthetic NT-proBNP(1-76) and antiserum directed to the carboxy-terminal end (amino acids 62-76) of NT-proBNP (lower panel). [fractions 64 -71] earlier than synthetic nonglycosylated NT-proBNP(1-76) [fraction 73], consistent with its probable glycosylation. Using reversed-phase HPLC, we also identified a broad peak with NTproBNP immunoreactivity in heart failure urine [fractions 60 -64] (Fig. 4) eluting earlier relative to synthetic NT-proBNP [at fraction 76] compared with endogenous NT-proBNP in plasma.
NT-proBNP IN HUMAN URINE
Healthy subjects. Urine NT-proBNP was below the assay limit of detection (5 ng/L) in all healthy subjects and 3 (6%) patients with heart failure. In 10 healthy subjects (2 men, ages 22-53 years), the median urine NT-proBNP index was less than 4.2 (IQR 2.6 -5.8) pg/mg creatinine.
Subjects with heart failure. Table 1 shows the clinical characteristics of the patients with heart failure who participated in the study. The median urine NTproBNP indexed to creatinine was higher in patients with acute and chronic heart failure than in healthy subjects (P Ͻ 0.001 for both comparisons). Urine NT-proBNP concentrations were also significantly higher in patients with acute compared with chronic heart failure (P ϭ 0.003) ( b P values represent group comparisons between acute heart failure and chronic heart failure status using 2 or independent t-tests. NS, not significant; NYHA, New York Heart Association. tricular ejection fraction (n ϭ 40, r ϭ Ϫ0.33, P ϭ 0.04) and eGFR (n ϭ 40, r ϭ Ϫ0.45, P ϭ 0.004) across the eGFR range of 18 -107 mL/min/1.73m 2 (Fig. 5) . Plasma NT-proBNP was also inversely correlated with left ventricular ejection fraction (n ϭ 40, r ϭ Ϫ0.48, P Ͻ 0.01) and eGFR (n ϭ 40, r ϭ Ϫ0.38, P ϭ 0.01). Median fractional excretion of filtered NT-proBNP was 6.3% (IQR 3.3%-19.9%) and was inversely correlated with eGFR (n ϭ 40, r ϭ Ϫ0.41, P ϭ 0.009) but not with left ventricular ejection fraction (n ϭ 35, r ϭ Ϫ0.05, P ϭ 0.77) or plasma NT-proBNP immunoreactivity (n ϭ 40, r ϭ 0.13, P ϭ 0.45).
Discussion
We used HPLC, coupled to multiple RIAs incorporating antisera raised toward a range of epitopes of NTproBNP(1-76), to characterize NT-proBNP forms in the urine of patients with acute heart failure. We validated a commercial assay for determination of urine NT-proBNP levels. Our data indicate that immunoreactive NT-proBNP is present in human urine as multiple fragments of the 76 -amino acid peptide. We confirmed previous work showing that urine NT-proBNP immunoreactivity correlates with concurrent plasma concentrations (11, 12, 16 ) in patients with heart failure, is significantly increased in patients with heart failure compared with healthy controls (11, 12, 15, 16 ) , and correlates inversely with left ventricular ejection fraction (13 ) and creatinine clearance (12 ) .
The sources of NT-proBNP fragments in human urine are unknown. At a MW of 8.5 kDa (or even twice that if heavily glycosylated) and possessing a neutral charge at pH 7.4 (29 ) , NT-proBNP is likely to be freely filtered at the glomerulus and may undergo subsequent proteolysis in urine. Additionally, NT-proBNP may undergo degradation by renal tubular cells. The lack of correlation between eGFR and fractional renal NTproBNP extraction across a broad range of kidney function (30 ) favors a contribution from tubular metabolism and secretion rather than glomerular filtration alone as the major renal clearance mechanism for circulating NT-proBNP. The observation in the current study, that urinary NT-proBNP indexed to creatinine was more discriminating for acute heart failure than urinary NT-proBNP concentration alone, is consistent with this conclusion. Markedly reduced concentrations of NT-proBNP in urine compared with plasma are also consistent with a cellular proteolytic mechanism for renal NT-proBNP clearance. In the current study, the inverse relationship between both urine NT-proBNP immunoreactivity and fractional excretion of filtered NT-proBNP to eGFR suggests that renal NT-proBNP clearance is increased rather than decreased with decreasing eGFR, but does not define the mechanisms by which degraded immunoreactive NT-proBNP enters the urinary space. Although not definitive, these data are consistent with upregulated renal excretion of circulating NT-proBNP associated with reducing renal function.
Renal tubular epithelial cells possess numerous peptidases, including enzymes that are known to degrade BNP (31 ) . These include the membrane-bound Scatter plots indicate relationships between urinary NTproBNP index in heart failure subjects and left ventricular ejection fraction (B) and estimated glomerular filtration rate (GFR) (C). ***P Ͻ 0.001; **P Ͻ 0.01. metalloprotease neutral endopeptidase (EC 3.4.24.11) (32 ) and the transmembrane serine protease, dipeptidyl peptidase IV (DPP4) (EC 3.4.14.5) (33, 34 ) that degrades peptides where proline or alanine is the penultimate amino terminal residue (35 ) . ProBNP(1-108) and its cleavage products NT-proBNP(1-76) and BNP(77-108) all have proline as the second aminoterminal residue and are known (23, 36 ) or potential substrates for DPP4 amino-terminal degradation. Substantially lower urine NT-proBNP concentrations in HPLC fractions identified by the NT-proBNP(1-13) (amino-terminal specific) assay compared with midpeptide assays (Roche proBNP first-and secondgeneration assays) is consistent with DPP4-mediated degradation of NT-proBNP. DPP4 is present in both glomerular epithelial (37 ) and renal tubular (38 ) cells and may play a role in renal metabolism of NT-proBNP before urinary excretion.
In reversed-phase HPLC, all immunoreactive urine NT-proBNP eluted ahead of a synthetic (and nonglycosylated) NT-proBNP(1-76) standard and relatively earlier than NT-proBNP in plasma. Taken together with our size-exclusion results, the data suggest that NT-proBNP present in plasma has a greater molecular weight than the forms in urine of these subjects with heart failure. Glycosylation of NT-proBNP may account for its early elution on reversed-phase HPLC. In any case, it is clear that the urine and plasma NTproBNP forms are different.
Analysis of patients with documented heart failure and healthy controls confirmed that urine NT-proBNP concentrations are increased in heart failure (11, 12, 15, 16 ) . The inverse relationship between urine NT-proBNP and left ventricular ejection fraction, together with correlations between plasma and urine concentrations in heart failure, suggests that urine NT-proBNP immunoreactivity is a potential biomarker in heart failure, as previously suggested (11) (12) (13) (14) (15) (16) (17) . Urine concentrations may reflect severity of cardiac decompensation. Accordingly, urine NT-proBNP values represent a potential screening tool for the presence of heart failure.
A single landmark study has evaluated the utility of urine NT-proBNP concentrations to exclude left ventricular systolic dysfunction (LVSD) assessed by echocardiography (n ϭ 1308, prevalence of LVSD 2.1%) in a community population without antecedent heart failure (15 ) . In the study, using a noncompetitive immunoluminometric assay (11 ), a urine NT-proBNP index of 0.16 pg/mg creatinine was comparable to plasma NT-proBNP (cutoff value of 222 ng/L) as a screening tool to exclude LVSD, with positive and negative predictive values for presence of LVSD of 5.7% and 99.8%, respectively. The utility of urine NTproBNP concentrations to detect heart failure (as opposed to detection of LVSD) in an unselected symptomatic population, however, remains to be assessed and is necessary before the diagnostic test accuracy of urine NT-proBNP for diagnosis of heart failure is known.
In conclusion, degradation of circulating plasma NT-proBNP in renal tissue before excretion in urine is likely to contribute to renal clearance, although the mechanisms remain to be elucidated. Clinical studies of urine NT-proBNP values in dyspneic patients, as previously conducted for plasma NT-proBNP (39, 40 ) , are now needed to determine the diagnostic test accuracy of urine NT-proBNP for the detection or exclusion of heart failure in symptomatic patients. There is little, if any, intact NT-proBNP(1-76) present in heart failure urine, and therefore immunoreactivity will vary according to the epitopes to which assorted antisera bind. The diagnostic performance of NT-proBNP assays applied to urine may be assay specific, necessitating analysis of biomarker performance on an assayby-assay basis.
